CAS No. |
1447799-33-8 |
|---|---|
中文名称 |
(5S,8S,11S,14S,17S,20S,23R)-5-((S)-1-((S)-2-((R)-2-氨基丙酰胺基)-3-羟基丙酰基)吡咯烷-2-羧酰胺基)-20-(羧甲基)-17-(4-羟基苄基)-8-(2-甲基丙基)-11-(丙-2-基)-14,23-二甲基-6,9,12,15,18,21-六氧代-2-硫杂-7,10,13,16,19,22-六氮杂二十四烷-24-酸 |
英文名称 |
(5S,8S,11S,14S,17S,20S,23R)-5-((S)-1-((S)-2-((R)-2-Aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetracosan-24-oic acid |
别名 |
Reltecimod;Reltecimod (peptide);D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-;P-2TA;P2TA |
标准英文名 |
(S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(D-alanyl-L-seryl)pyrrolidine-2-carboxamido)-4-(methylthio)butanamido)-4-methylpentanamido)-3-methylbutanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-4-(((R)-1-carboxyethyl)amino)-4-oxobutanoic acid |
分子式 |
C46H72N10O15S |
分子量 |
1037.20 |
精确分子量 |
1036.49 |
SMILES |
O=C(N[C@@H](C(O)=O)C)[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]1N(C([C@@H](NC([C@H](N)C)=O)CO)=O)CCC1)=O)CCSC)=O)CC(C)C)=O)C(C)C)=O)C)=O)CC2=CC=C(O)C=C2)=O)CC(O)=O |
标准SMILES |
CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(O)=O |
用途 |
Reltecimod is a peptide used for the treatment of severe necrotizing soft tissue infections caused by flesh-eating bacteria; currently in Phase III clinical trials. |
InChIKey |
VRNHFZYMPDKTBS-WYUJEMNCSA-N |
|
|
评论 |
|---|